1 / 31

Corporate Social Responsibility

Corporate Social Responsibility. Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.

hedwig
Télécharger la présentation

Corporate Social Responsibility

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation

  2. The number of people with diabetes in the world is expected to rise from 177 million today to 370 million in 203076% of the total number of people with diabetes worldwide will be living in the developing countries

  3. The developing countries carry 90% of this world’s total disease burden, yet they benefit from only 10% of global health resources WHO estimates that 1/3 of the world population lacks regular access to essential drugs, and this figure is expected to rise to over 50% in the least developed parts of Africa and Asia

  4. WHO states that non-communicable diseases such as diabetes are the world’s main disablers and killers already now

  5. Epidemiology: Burden of diabetes is increasing • Increased childhood and adult obesity • Decreasing levels of physical activity • Increasing urbanisation • Increased longevity • Earlier diagnosis • A new patient is diagnosed with type 2 diabetes every 5 minutes Epidemic(WHO, 1997)

  6. The sufferings from diabetes • Life expectancy is reduced by 5 to 10 years • Premature death due to myocardial disease X 4 • Stroke is increased X 2 • Renal failure: 40% of all dialysed patients have diabetes • New blindness: 30% of all cases are people with diabetes • (>90% of these have type 2 diabetes) • Two out of three amputees have diabetes

  7. The financial costs of diabetes ”With the present trend diabetes and its complications, will take more than one third of the health budgets in only 15 to 20 years – if vigorous steps to slow the progress of this ’epidemic’ are not taken” S. Orahilly, Science, medicine and the future. Non-insulin-dependent diabetes mellitus: the gathering storm. BMJ March 1997

  8. What can a diabetes company do?

  9. The Triple Bottom Line Economically viable • Financial • Socio-& health economics Socially responsible Environmentally sound • Employees • Patients • Communities • Environment • Animals • Bioethics

  10. Access to health in developing countries WHO recommendations: • Development of national health strategies • Building of national healthcare capacity • Best possible pricing • Additional funding

  11. Diabetes a national priority?

  12. Diabetes prevention programme NCD Unit for prevention /control National survey for hypertension No surveillance system nationally NCD policy Budget line for NCD Integrated primary care prevention NCD info in annual report Focus on chronic diseases? (167 countries) Alwan 2001

  13. National Diabetes Strategies programme • Novo Nordisk facilitates development and collaboration on the implementation of national strategies for diabetes prevention and treatment • We aim at identifying best practices from around the world • The programme is systematic and can be a template for the other chronic diseases (CVD, hypertension)

  14. Understanding patients needs

  15. DAWN- A study to understand… • People with diabetes • Feelings, worries, wishes and needs • Perceptions of their diabetes • Health care professional attitudes • Role of psychosocial factors

  16. Best Pricing

  17. Pricing Policy in LDC Countries • Novo Nordisk offers its insulin products to the public health systems in the poorest countries at prices not to exceed 20% of the average price in North America, Europe and Japan LDC as defined by UN: 49 countries in Africa, Asia-Pacific and Central America

  18. Additional funding

  19. The World Diabetes Foundation founded in March2002Initiated by a grant from Novo Nordisk of USD 80 million Majority of board members – non Novo NordiskChairman: Professor Pierre Lefèbvre26 projects funded to date

  20. WDF is dedicated to prevention and treatment of diabetes in the poorest countries with focus on:Awareness about diabetesPrevention of diabetes and its complications Education and training for patients and professionalsAccess to essential diabetes medicationDetection, treatment and monitoring of diabetes

  21. The role of the World Diabetes Foundation Creates partnerships and acts as a catalyst Links people and resources to advocate globally and provide care locally Aims at the poorest of the poor Focuses on innovative strategies to prevent diabetes Strives to achieve sustainable solutions

  22. Regional projects in WDF portfolio • Diabetes Education, Sub-Saharan Africa • Clinical Practice Guidelines, Sub-Saharan Africa • WDF/IDF Fellowships • Nutrition Protocol, the Caribbean • Postgraduate diabetes training, Africa

  23. Local projects in WDF portfolio • Cameroon: National Diabetes Programme • China: National Diabetes Programme • India: Diabetes Eye Care • India: National Diabetes Programme • India/Tanzania: Diabetes Foot Care • India: Rural and semi-urban diabetes prevention and control • Tanzania: 15 Diabetes Clinics • Mozambique: Insulin Availability • West Bank: Diabetes Prevention and Nutrition • Cuba: Regional Diabetes Centers • Congo / Kinshasa: Insulin Availability • Vietnam: National Diabetes Project • Bolivia: Diabetes Centre • Nepal: Diabetes Education and Prevention • Bhutan: Diabetes health care services • Pacific Islands: Reducing diabetes complications

  24. Memorandum of Understanding with DANIDA- Danish International Development AgencyThe objective of the partnership is to combat diabetes in the developing countriesLead to the identification of two projects in India and Bhutan

  25. Application criteriaSustainabilityLocal championPolitical willCo-fundingApplication form on www.worlddiabetesfoundation.org

  26. Multiplier effectProject portfolio:21 million USD of which 12 million USD were donated by the World Diabetes Foundation

  27. ImpactThe projects funded by the World Diabetes Foundation will in the coming 3-4 years potentially influence the diabetes treatment of 18,000.000 people directly and indirectly 50,000,000 people in the developing countries

  28. “The hottest places in Hell are reserved for those who, in time of great moral crisis, maintain their neutrality” Dante

  29. “…Governments only find the courage and resources to do the right thing when business takes the lead.” Kofi Annan

  30. Need for a new and different understanding of the disease • Need for a new social equation in disease management • An urgent need that governments, scientists, corporations, patients join forces against the disease Thank you!

More Related